Zhang Wen, Wang Feifei, Hu Xiao, Liang Jing, Liu Binlei, Guan Qi, Liu Shangmei
Department of Immunology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, P.R. China.
Inner Mongolia University For Nationalities, Tongliao, Inner Mongolia 028000, P.R. China.
Oncol Lett. 2019 Jan;17(1):815-822. doi: 10.3892/ol.2018.9720. Epub 2018 Nov 16.
Liver metastasis represents the most prominent metastasis of colorectal cancer (CRC) and is the leading cause of CRC mortality, making the early prevention of this event very important. While current CRC therapies include surgery, radiotherapy and chemotherapy, no effective treatment option for CRC liver metastasis (CRLM) exists. Furthermore, the effects of currently available metastatic CRC drugs are frequently limited by their toxicity and side effects. Oncolytic herpes simplex virus type 2 (oHSV2) selectively infects tumor cells and also induces an antitumor immune response. The present study investigated the cytopathic effects of oHSV2 on CT-26 cells and tested its inhibitory effect on CRLM. experimental data demonstrated that oHSV2 effectively inhibited the growth of CT-26 cells. study data demonstrated that treatment with oHSV2 alone slowed the growth of subcutaneous xenograft tumors without inducing weight loss and also inhibited CRLM by increasing the numbers of cluster of differentiation (CD)4 T, CD8+ T and natural killer cells. In summary, oHSV2 shows potential as a safe and effective therapeutic agent for inhibiting the metastasis of CT-26 CRC cells to the liver.
肝转移是结直肠癌（CRC）最主要的转移方式，也是CRC患者死亡的主要原因，因此早期预防这一情况非常重要。虽然目前CRC的治疗方法包括手术、放疗和化疗，但对于CRC肝转移（CRLM）尚无有效的治疗方案。此外，目前可用的转移性CRC药物的疗效常常受到其毒性和副作用的限制。溶瘤性单纯疱疹病毒2型（oHSV2）可选择性感染肿瘤细胞，并诱导抗肿瘤免疫反应。本研究调查了oHSV2对CT-26细胞的细胞病变效应，并测试了其对CRLM的抑制作用。实验数据表明，oHSV2可有效抑制CT-26细胞的生长。研究数据表明，单独使用oHSV2治疗可减缓皮下异种移植瘤的生长，且不会导致体重减轻，还可通过增加分化簇（CD）4 T细胞、CD8+ T细胞和自然杀伤细胞的数量来抑制CRLM。总之，oHSV2显示出作为一种安全有效的治疗剂来抑制CT-26 CRC细胞向肝脏转移的潜力。
